Kisqali (with fulvestrant) (ribociclib with fulvestrant)

pCPA File Number: 21218

Negotiation Status:

Concluded with an LOI

Indication(s):

Advanced or Metastatic Breast Cancer

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CADTH Project Number:

pCODR 10195

pCPA Engagement Letter Issued:

2020-05-11

Negotiation Process Concluded:

2020-07-14